Media Hub

View the latest content of the NASH Summit Boston and other events of the Fibrosis Series

interview nash

I N D U S T R Y    I N S I G H T S    S E R I E S

A N   I N T E R V I E W    W I T H
P H Y S I O G E N E X

François Briand, Director, Research & Business Development, Physiogenex

NASH Summit FDA Presentation First Page

An exclusive FDA presentation by:

Dr Frank A. Anania, Acting Clinical Team Leader, Division of Gastroenterology and Inborn Error Products, FDA

future of nash

Laurent Fischer, MD Senior Vice President, Liver Therapeutic Area Head, ALLERGAN PLC

ON THE THRESHOLD OF A THERAPEUTIC MILESTONE

Capturedefef resized

Peter G. Traber, MD Partner, Alacrita Consulting : NASH Now: Therapeutic Targets & the Competitive Clinical Trial Landscape

nash3

Brent A. Neuschwander-Tetri, Professor of Internal Medicine - Saint Louis University. : Many Paths to NASH- Many Targets for Treatment

Capture7899

Yury Popov, MD PhD, Beth Israel Deaconess Medical Center, Harvard Medical School: Understanding Hepatocellular Carcinoma as an Extension of NASH: practical implications for drug development

Capture89

Liat Hayardeny, Chief Scientific Officer, Galmed Pharmaceuticals: Aramchol Phase II b Results & Phase III Outlook

Capture78

Greg Everson, Chief Executive Officer & Manager, HepQuant: Tests of the Liver’s Function and Physiology to Assess Liver Disease and Monitor Treatment Effects

Capture788

Nikolai Naoumov, MD PhD, Exucutive Director - Hepatology Science& Innovation, Global Drug Development Novartis Pharma: Which Mechanisms of Action to Combine to Address NASH

Capture56

Eric Lefebvre, Chief Medical Officer - Pliant Therapeutics Inc. : Disruption of TGF β activation by an α V β 1 integrin inhibitor reduces liver fibrosis in human NASH liver slices and mice

NASH 2019 - Speaker Interview - Resar Cenar

NASH one pager

Speaker interview-resar cenar
one-pagerr-NASH

Who attended in 2019 

Global Liver Institute, Donna Cryer

whos-attending-3rd NASH snippet
Global Liver Institute

Targeting multiple pathways in NASH - clinical perspectives for combination therapies | Nikolai Naoumov

Molecular MR Imaging of Oxidized Collagen to Monitor Active Fibrogenesis in Preclinical Models of NASH | Bryan Fuchs

Targeting multiple pathways
Molecular MR Imaging

Evaluating Progression Towards Industry Standard In Vitro Models of NAFLD/NASH

In Vitro